Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 16 Researches
7.1
USERS' SCORE
Good
Based on 24 Reviews
8.6
Supplement Facts
Serving Size: 1 Veg Capsule
Amount Per Serving
%DV
Vitamin K2 (as Menaquinone-4) (MK-4)
100 mcg
**
Alfalfa Powder (Aerial Parts)
250 mg
**
Top Medical Research Studies
8
We evaluated the effectiveness of vitamin K antagonists (VKAs) in treating left ventricular thrombosis (LVT). Over a year, a cohort of 90 patients was observed for LVT resolution and complications.
By the end of the study, approximately 70% of participants saw their blood clots resolve, with lower success rates linked to factors like reduced heart function. While VKAs showed promise, the treatment's safety profile was also notable, with few severe complications reported.
By the end of the study, approximately 70% of participants saw their blood clots resolve, with lower success rates linked to factors like reduced heart function. While VKAs showed promise, the treatment's safety profile was also notable, with few severe complications reported.
Read More
8
Thrombosis incidence varies by anticoagulant
We investigated the incidence of bioprosthetic mitral valve thrombosis (bMVT) after transcatheter and surgical mitral valve replacements. Analyzing data from 47 studies involving over 6,000 patients revealed that bMVT occurs more frequently in patients undergoing transcatheter procedures, though not significantly.
Interestingly, those treated with vitamin K antagonists experienced a notably lower incidence of bMVT compared to those on direct oral anticoagulants. This suggests that the choice of anticoagulant could influence thrombotic risks after these heart surgeries.
Interestingly, those treated with vitamin K antagonists experienced a notably lower incidence of bMVT compared to those on direct oral anticoagulants. This suggests that the choice of anticoagulant could influence thrombotic risks after these heart surgeries.
Read More
7
VKA treatment outcomes in atrial fibrillation
Our study involved a group of 1,350 patients with valvular and nonvalvular atrial fibrillation, all receiving vitamin K antagonists (VKAs). Over about 17 months, we noted an annual incidence of 4.4% for serious events like cardiovascular death and thromboembolic occurrences.
Key predictors included a history of thromboembolism and bleeding, low time in therapeutic range, and reduced kidney function. Notably, while VKAs are crucial, they come with risks that we need to monitor closely to improve patient outcomes.
Key predictors included a history of thromboembolism and bleeding, low time in therapeutic range, and reduced kidney function. Notably, while VKAs are crucial, they come with risks that we need to monitor closely to improve patient outcomes.
Read More
Most Useful Reviews
9
Normal clotting restored
478 people found this helpful
A friend experienced poor blood clotting and was prescribed these vitamins. After two months of use, everything has returned to normal.
Read More
9
Prevents haemorrhagic issues
12 people found this helpful
Vitamin K2 is essential, especially for pregnant women and newborns, to reduce the risk of haemorrhagic issues during childbirth. I believe it's crucial due to its role in preventing more severe consequences related to calcium deposits and blood clotting.
Read More
9
Protects against kidney stones
6 people found this helpful
I take vitamin K2 alongside D3 to prevent kidney stones. These vitamins work together, allowing calcium to reach bones instead of depositing in blood vessels. I feel energised since starting this regimen.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 16 Researches
7.1
- All Researches
8
We examined a narrative review that highlights the effectiveness and safety of the four-factor prothrombin complex concentrate (4F-PCC), particularly Octaplex/Balfaxar. This treatment is designed to enhance clot formation and is available for reversing the effects of vitamin K antagonists like warfarin.
Over 20 years of clinical use revealed that 4F-PCC significantly lowers the international normalized ratio (INR) in patients, helping them achieve better clotting. Interestingly, only a couple of treatment-related thrombotic events were noted, indicating a balanced approach toward clotting without excessive risk.
Over 20 years of clinical use revealed that 4F-PCC significantly lowers the international normalized ratio (INR) in patients, helping them achieve better clotting. Interestingly, only a couple of treatment-related thrombotic events were noted, indicating a balanced approach toward clotting without excessive risk.
Read More
8
We evaluated the effectiveness of vitamin K antagonists (VKAs) in treating left ventricular thrombosis (LVT). Over a year, a cohort of 90 patients was observed for LVT resolution and complications.
By the end of the study, approximately 70% of participants saw their blood clots resolve, with lower success rates linked to factors like reduced heart function. While VKAs showed promise, the treatment's safety profile was also notable, with few severe complications reported.
By the end of the study, approximately 70% of participants saw their blood clots resolve, with lower success rates linked to factors like reduced heart function. While VKAs showed promise, the treatment's safety profile was also notable, with few severe complications reported.
Read More
8
We aimed to find the best antithrombotic regimen for patients with atrial fibrillation (AF) who recently experienced acute coronary syndrome (ACS) or had a percutaneous coronary intervention (PCI).
In our analysis of a randomized clinical trial, we compared apixaban, a novel anticoagulant, to vitamin K antagonists and evaluated the overall safety and efficiency of these treatments.
Our results showed that apixaban effectively reduced major bleeding events without increasing ischemic risks compared to vitamin K. We recommend using apixaban with a low-potency P2Y inhibitor as the standard care approach.
In our analysis of a randomized clinical trial, we compared apixaban, a novel anticoagulant, to vitamin K antagonists and evaluated the overall safety and efficiency of these treatments.
Our results showed that apixaban effectively reduced major bleeding events without increasing ischemic risks compared to vitamin K. We recommend using apixaban with a low-potency P2Y inhibitor as the standard care approach.
Read More
8
Thrombosis incidence varies by anticoagulant
We investigated the incidence of bioprosthetic mitral valve thrombosis (bMVT) after transcatheter and surgical mitral valve replacements. Analyzing data from 47 studies involving over 6,000 patients revealed that bMVT occurs more frequently in patients undergoing transcatheter procedures, though not significantly.
Interestingly, those treated with vitamin K antagonists experienced a notably lower incidence of bMVT compared to those on direct oral anticoagulants. This suggests that the choice of anticoagulant could influence thrombotic risks after these heart surgeries.
Interestingly, those treated with vitamin K antagonists experienced a notably lower incidence of bMVT compared to those on direct oral anticoagulants. This suggests that the choice of anticoagulant could influence thrombotic risks after these heart surgeries.
Read More
8
NOACs outperform VKAs in treatment
We examined how novel oral anticoagulants (NOACs) compare to vitamin K antagonists (VKAs) in treating blood clots in patients with nonvalvular atrial fibrillation.
In our review of 12 studies with nearly 1,000 participants, we found that NOACs achieved better clot-clearing results than VKAs, with a rate of 78% compared to 64%. Importantly, there were no significant differences in safety between these treatments.
Thus, NOACs appear to be a more effective option without increasing adverse events, suggesting a promising alternative for managing blood clots in these patients.
In our review of 12 studies with nearly 1,000 participants, we found that NOACs achieved better clot-clearing results than VKAs, with a rate of 78% compared to 64%. Importantly, there were no significant differences in safety between these treatments.
Thus, NOACs appear to be a more effective option without increasing adverse events, suggesting a promising alternative for managing blood clots in these patients.
Read More
User Reviews
USERS' SCORE
Good
Based on 24 Reviews
8.6
- All Reviews
- Positive Reviews
- Negative Reviews
9
Normal clotting restored
478 people found this helpful
A friend experienced poor blood clotting and was prescribed these vitamins. After two months of use, everything has returned to normal.
Read More
9
Prevents haemorrhagic issues
12 people found this helpful
Vitamin K2 is essential, especially for pregnant women and newborns, to reduce the risk of haemorrhagic issues during childbirth. I believe it's crucial due to its role in preventing more severe consequences related to calcium deposits and blood clotting.
Read More
9
Protects against kidney stones
6 people found this helpful
I take vitamin K2 alongside D3 to prevent kidney stones. These vitamins work together, allowing calcium to reach bones instead of depositing in blood vessels. I feel energised since starting this regimen.
Read More
9
Reduced clots
1 people found this helpful
Vitamin K2 saved my life. I suffered from severe period clots, but after taking vitamin K2, the clots reduced drastically. Now I can go out without fear. The ingredients are clean, the size is small, and one dosage a day is perfect. This pill has greatly benefited me.
Read More
9
Health benefits
1 people found this helpful
This is the best vitamin K2 from my preferred brand, known for its high quality. Vitamin K2 regulates metabolic processes, supports blood vessel health, and aids blood coagulation by improving insulin production and boosting immunity. The recommended dose is one capsule daily. I recommend it!
Read More
Frequently Asked Questions
9
Normal clotting restored
478 people found this helpful
A friend experienced poor blood clotting and was prescribed these vitamins. After two months of use, everything has returned to normal.
9
Reduced clots
1 people found this helpful
Vitamin K2 saved my life. I suffered from severe period clots, but after taking vitamin K2, the clots reduced drastically. Now I can go out without fear. The ingredients are clean, the size is small, and one dosage a day is perfect. This pill has greatly benefited me.
6
Distributes calcium correctly
3 people found this helpful
I take K2 to manage calcium effectively, targeting arteries and bones to prevent atherosclerosis. I’ve used it for three consecutive bottles and hope to see positive results in my arteries after a medical check.
9
Protects against kidney stones
6 people found this helpful
I take vitamin K2 alongside D3 to prevent kidney stones. These vitamins work together, allowing calcium to reach bones instead of depositing in blood vessels. I feel energised since starting this regimen.
7.5
Coagulation aid
1 people found this helpful
I took this vitamin alongside vitamin D3. They work excellently together. Vitamin K plays an essential role in blood clotting as it participates in forming proteins in the liver and aids bone formation by activating calcium binding in bone tissue. The benefits are plentiful, and the taste is neutral.
7.5
Bone health support
3 people found this helpful
I take it because I consume vitamin D to prevent calcium buildup in the arteries. Its essential role is to return calcium to the bones and teeth. Over time, I've noticed an improvement in the strength of my jaw, teeth, and bones. Glory be to God.
7.5
Regulates blood clotting
6 people found this helpful
Vitamin K2 is beneficial for everyone to take twice a year. It directs calcium to bones and teeth while cleaning blood vessels. Together with D3, they balance and regulate blood clotting effectively.
7.5
Calcium distribution improvement
7 people found this helpful
This high-quality vitamin K2 works best when combined with magnesium and Vitamin D3. It ensures proper calcium distribution throughout the body and supports blood vessel health. It's crucial to take K2 separately from Vitamin D3 for optimal results.
8
We evaluated the effectiveness of vitamin K antagonists (VKAs) in treating left ventricular thrombosis (LVT). Over a year, a cohort of 90 patients was observed for LVT resolution and complications.
By the end of the study, approximately 70% of participants saw their blood clots resolve, with lower success rates linked to factors like reduced heart function. While VKAs showed promise, the treatment's safety profile was also notable, with few severe complications reported.
By the end of the study, approximately 70% of participants saw their blood clots resolve, with lower success rates linked to factors like reduced heart function. While VKAs showed promise, the treatment's safety profile was also notable, with few severe complications reported.
8
We examined a narrative review that highlights the effectiveness and safety of the four-factor prothrombin complex concentrate (4F-PCC), particularly Octaplex/Balfaxar. This treatment is designed to enhance clot formation and is available for reversing the effects of vitamin K antagonists like warfarin.
Over 20 years of clinical use revealed that 4F-PCC significantly lowers the international normalized ratio (INR) in patients, helping them achieve better clotting. Interestingly, only a couple of treatment-related thrombotic events were noted, indicating a balanced approach toward clotting without excessive risk.
Over 20 years of clinical use revealed that 4F-PCC significantly lowers the international normalized ratio (INR) in patients, helping them achieve better clotting. Interestingly, only a couple of treatment-related thrombotic events were noted, indicating a balanced approach toward clotting without excessive risk.
5
DOACs and VKAs show similar effectiveness
We looked into the effectiveness and safety of direct oral anticoagulants (DOACs) compared to vitamin K antagonists (VKAs) for cerebral venous thrombosis treatment. Conducted in 65 hospitals across 23 countries, this study found that the occurrence of major bleeding or recurrent clots was similar between both treatment options.
With over 600 patients involved, we observed that only a small percentage experienced these adverse outcomes within six months. Thus, both DOACs and VKAs appear to be valid choices for treating this condition, offering new insights into patient care.
With over 600 patients involved, we observed that only a small percentage experienced these adverse outcomes within six months. Thus, both DOACs and VKAs appear to be valid choices for treating this condition, offering new insights into patient care.
8
NOACs outperform VKAs in treatment
We examined how novel oral anticoagulants (NOACs) compare to vitamin K antagonists (VKAs) in treating blood clots in patients with nonvalvular atrial fibrillation.
In our review of 12 studies with nearly 1,000 participants, we found that NOACs achieved better clot-clearing results than VKAs, with a rate of 78% compared to 64%. Importantly, there were no significant differences in safety between these treatments.
Thus, NOACs appear to be a more effective option without increasing adverse events, suggesting a promising alternative for managing blood clots in these patients.
In our review of 12 studies with nearly 1,000 participants, we found that NOACs achieved better clot-clearing results than VKAs, with a rate of 78% compared to 64%. Importantly, there were no significant differences in safety between these treatments.
Thus, NOACs appear to be a more effective option without increasing adverse events, suggesting a promising alternative for managing blood clots in these patients.
References
- Karkouti K, Gareis M, Li C, Brandstätter H, Pichotta A, et al. Twenty years of the four-factor prothrombin complex concentrate Octaplex/Balfaxar: A narrative review. Transfus Apher Sci. 2025;64:104115. doi:10.1016/j.transci.2025.104115
- Valeriani E, Astorri G, Pannunzio A, Pastori D, Palumbo IM, et al. Long-term left ventricular thrombosis resolution in patients receiving vitamin k antagonists: a multicenter observational study. Intern Emerg Med. 2025. doi:10.1007/s11739-025-03922-6
- Geertsema-Hoeve BC, Radin M, Sciascia S, Urbanus RT, Huisman A, et al. Problem Solved? An Individual Ratio between Point-of-Care and Venous International Normalized Ratio Values in Two Patients with Antiphospholipid Syndrome: Two Case Reports. TH Open. 2025;9:a25425358. doi:10.1055/a-2542-5358
- Last J, Birschmann I, Lindau S, Konstantinides S, Grottke O, et al. Anticoagulant Management After Emergency Surgery or Major Bleeding in Anticoagulated Patients-Results of the Prospective RADOA Registry. Pharmaceuticals (Basel). 2025;18. doi:10.3390/ph18020170
- van de Munckhof A, van Kammen MS, Tatlisumak T, Krzywicka K, Aaron S, et al. Direct oral anticoagulants versus vitamin K antagonists for cerebral venous thrombosis (DOAC-CVT): an international, prospective, observational cohort study. Lancet Neurol. 2025;24:199. doi:10.1016/S1474-4422(24)00519-2
- Liporace IL, Oliveira GBF, Alves LBO, Galassi NM, Jeronimo AD, et al. Incidence and Predictors of Clinical Outcomes in Patients with Valvular and Nonvalvular Atrial Fibrillation Using Vitamin K Antagonists. Arq Bras Cardiol. 2025;122:e20240147. doi:10.36660/abc.20240147
- Hall EH, Sølsnes MH, Sandberg S, Sølvik UØ. Patient self-management of warfarin therapy - a long-term follow up study. Thromb J. 2025;23:14. doi:10.1186/s12959-025-00694-z
- Liu Y, Lam SHM, Romiti GF, Huang B, Chen Y, et al. Renal function and adverse clinical events in anticoagulated patients with atrial fibrillation: insights from the GLORIA-AF Registry Phase III. J Thromb Thrombolysis. 2025;58:165. doi:10.1007/s11239-025-03067-5
- Tannu M, Lopes RD, Wojdyla DM, Goodman SG, Aronson R, et al. Antithrombotic Therapy to Minimize Total Events After ACS or PCI in Atrial Fibrillation: Insights From AUGUSTUS. J Am Coll Cardiol. 2025;85:1157. doi:10.1016/j.jacc.2024.10.125
- Zorman MJ, Vibhishanan J, Dangas K, Castle J, Li KHC, et al. Valve Thrombosis and Antithrombotic Therapy After Bioprosthetic Mitral Valve Replacement: A Systematic Review And Meta-Analysis. Eur Heart J Cardiovasc Pharmacother. 2025. doi:10.1093/ehjcvp/pvaf005
- Mo GL, Wen J, Ye YY, Lu YQ, Gan TM, et al. Efficacy and Safety of New Oral Anticoagulants versus Warfarin in the Resolution of Atrial Fibrillation with Left Atrial/Left Atrial Appendage Thrombus: A Systematic Review and Meta-Analysis. Rev Cardiovasc Med. 2025;26:26055. doi:10.31083/RCM26055
- Kempers EK, Visser C, Geijteman ECT, Goedegebuur J, Portielje JEA, et al. Discontinuation of Anticoagulants and Occurrence of Bleeding and Thromboembolic Events in Vitamin K Antagonist Users with a Life-limiting Disease. Thromb Haemost. 2025. doi:10.1055/a-2524-5334
- Himmelreich JCL, Virdone S, Camm AJ, Pieper K, Harskamp RE, et al. Emulation of ARISTOTLE and ROCKET AF trials in real-world atrial fibrillation patients results in similar efficacy and safety as original landmark trials: insights from the GARFIELD-AF registry. Open Heart. 2025;12. doi:10.1136/openhrt-2024-002966
- Mapelli M, Celeste F, Maiolo G, Mancini E, Agostoni P. Incidental Diagnosis of Massive Mobile Left Ventricle Thrombi Following COVID-19 in a Heart Failure Patient. JACC Case Rep. 2024;29:102870. doi:10.1016/j.jaccas.2024.102870
- Gustafsson F, Uriel N, Netuka I, Katz JN, Pagani FD, et al. Aspirin and Hemocompatibility After LVAD Implantation in Patients With Atherosclerotic Vascular Disease: A Secondary Analysis From the ARIES-HM3 Randomized Clinical Trial. JAMA Cardiol. 2025;10:235. doi:10.1001/jamacardio.2024.4849
- Premkumar M, Bhujade H, Sharma P, Nain J, Ahluwalia J, et al. Experience With Dabigatran on Rate of Portal Vein Thrombosis Recanalization, Disease Progression and Survival. Aliment Pharmacol Ther. 2025;61:971. doi:10.1111/apt.18474
